Migraine Disorders Clinical Trial
Official title:
Optimizing the Effect of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Migraine
The aim of this study is to establish an optimized protocol of tDCS that normalize the lack of habituation and efficiency of inhibitory cortical circuits in migraine patients and determine tDCS polarity and the best cortical areas to stimulate which could normalize the lack of habituation and efficiency of inhibitory cortical circuits. For this, migraineurs volunteers will undergo to some tDCS protocols or sham tDCS.
Status | Recruiting |
Enrollment | 14 |
Est. completion date | April 2018 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Ages: 18-55 years - Gender: Both - Presented diagnostic of episodic migraine with or without aura or probably migraine with or without aura according to the criteria for diagnosis of ICHD-III - Disease duration of at least 12 months - Without preventive medication for at least 6 months prior to initiation of treatment Exclusion Criteria: - Pregnant women; - Pacemaker; - History of seizures; - Metallic implants in the head; - Patients with clinical evidence of brain injuries; - Chronic pain associated to others diseases; - Use of neuroleptic medications |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | Applied Neuroscience Laboratory | Recife | Pernambuco |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal de Pernambuco |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes on VAS | this scale will be used to measure the patients' pain intensity. VAS is an important instrument to verify, reliably, the patient's evolution during treatment. This scale will be used at beginning and end of each period (observation and treatment), before and after each tDCS session. For the VAS use, pain intensity will be asked to the patient. 0 cm means total pain absence and 10 cm is the level of maximum pain bearable by the patient. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Secondary | Changes on Visual Evoked Potentials measures | volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz. Electrodes used to record data will be localized on Oz and Fz points according International 10-20 system. During the test, 600 cortical answers will be recorded. Data will be collected and recorded in a personal computer, and after, converted to the ".txt" format to futures analysis with MATLAB. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Secondary | Changes on motor evoked potentials | to measure MEP, the intensity of the magnetic stimulator will be adjusted to 120% of rest motor threshold and 10 stimuli will be registered. For evaluation volunteers will be instructed to sit in a chair and get into a comfortable position. Initially, single-pulse TMS will be administered over the motor cortex to determine the cortical representation area of the first dorsal interosseous muscle (FDI). For all evaluations the same figure-eight coil is used, in order to avoid measurement bias. Amplitude means of evoked potentials will determine the MEP. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Secondary | Changes on intracortical inhibition | to evaluate these variables, subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at an inter stimulus intervals (ISI) of 2 milliseconds, to determine the short interval cortical inhibition (SICI). The Intracortical facilitation (ICF) will be evaluated by the MEP average at an ISI of 10 milliseconds. Ten stimulus will be applied in each condition (unconditioned pulse, and pairs of stimuli with ISI of 2 and 10 milliseconds). The order of stimulus delivered will be pseudorandomized and SICI and ICF will be expressed as a percentage of a conditioned stimuli in regarding an unconditioned stimuli. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Secondary | Changes on intracortical facilitation | to evaluate these variables, subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at an inter stimulus intervals (ISI) of 2 milliseconds, to determine the short interval cortical inhibition (SICI). The Intracortical facilitation (ICF) will be evaluated by the MEP average at an ISI of 10 milliseconds. Ten stimulus will be applied in each condition (unconditioned pulse, and pairs of stimuli with ISI of 2 and 10 milliseconds). The order of stimulus delivered will be pseudorandomized and SICI and ICF will be expressed as a percentage of a conditioned stimuli in regarding an unconditioned stimuli. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Secondary | Changes from phosphene threshold | a 10-cm circular coil was used that has giving a peak magnetic field strength of 2 tesla. Subjects were asked to wear a blindfold, sit comfortably in a chair and to close their eyes to diminish ambient light.In sagittal line, three points were scored: 2, 3 and 4 cm above the inion. The single pulse TMS was applied to one of the points scored and the subject was asked to report the presence or absence of a phosphene immediately after stimulation. The stimulation was repeated ten times at each intensity with a maximum frequency of 0.2 Hz, stimulation was initially applied to 60% of the maximum intensity of the stimulator. The intensity of stimulation was changed into blocks of 5% to minimum intensity that the subject can perceive the phosphene certainly, five times ten, then this value was set as the PT. | through study completion, assessed up to 3 weeks (before and after each section) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432379 -
BOTOX® Prophylaxis in Patients With Chronic Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05048914 -
Migraine Abortive Treatment
|
||
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT02766517 -
Biomarker Study in Participants With Migraine
|
Early Phase 1 | |
Completed |
NCT00963937 -
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
|
Phase 3 | |
Not yet recruiting |
NCT03632928 -
Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
|
||
Completed |
NCT02559895 -
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
|
Phase 3 | |
Completed |
NCT01435941 -
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
|
N/A | |
Completed |
NCT00743015 -
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
|
Phase 1 | |
Completed |
NCT01376141 -
Drug Use Investigation for IMIGRAN Tablet
|
N/A | |
Completed |
NCT02183688 -
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
|
Phase 3 | |
Completed |
NCT06061588 -
"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"
|
N/A | |
Completed |
NCT03588364 -
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
|
N/A | |
Completed |
NCT04091321 -
Association Between Chronic Headache and Back Pain With Childbirth
|
||
Completed |
NCT00385008 -
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
|
Phase 3 | |
Active, not recruiting |
NCT05888298 -
Proximal and Distal Approach GON RFT in Migraine
|
N/A | |
Completed |
NCT03435185 -
Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT02565186 -
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
|
Phase 3 |